Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A PHASE 1B STUDY OF CRIZOTINIB IN COMBINATION WITH PEMBROLIZUMAB (MK-3475) IN PATIENTS WITH UNTREATED ADVANCED ALK-TRANSLOCATED NON SMALL CELL LUNG CANCER

NCT02511184 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT02511184
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02511184 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A PHASE 1B STUDY OF CRIZOTINIB IN COMBINATION WITH PEMBROLIZUMAB (MK-3475) IN PATIENTS WITH UNTREATED ADVANCED ALK-TRANSLOCATED NON SMALL CELL LUNG CANCER
Lead sponsor
Pfizer
Phase
Phase 1
Overall status
Terminated
Start date
October 31, 2015
Completion date
December 31, 2017
Enrollment
9 (actual)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

alk-positive advanced nsclc